Summary
The phenolic lignans enterolactone and enterodiol appear periodically in women's urine, dependent upon synthesis from plant-derived lignans by the intestinal microflora. The phytoestrogen equol is also present in women's urine, and is also derived from a vegetarian diet. Antiestrogenic or antiproliferative actions of these compounds have been postulated and related to the observation that there is a reduced incidence of breast cancer associated with diet. We evaluated the estrogenic and antiestrogenic activity of these compounds using four sensitive assays in tissue culture, including the use of human breast cancer cell lines T47D and MCF-7. Unexpectedly, we found that enterolactone and enterodiol, as well as equol, are weak estrogens, and that enterolactone and equol could stimulate the growth of estrogen-dependent breast cancer cell lines. We suggest that these environmental agents can promote the growth of breast cancer, particularly hormone-dependent metastases that may be located near the gut or in the mesenteries or liver, where the concentration of these intestinally produced compounds would be highest. Treatment with an antiestrogen such as tamoxifen blocks the estrogenic activity of these compounds. In the absence of treatment with an antiestrogen such as tamoxifen, hormonal therapy to block steroidal estrogen synthesis in a patient with breast cancer could conceivably be circumvented by a vegeterian diet rich in the precursors to estrogenic compounds such as enterolactone and equol.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Stitch SR, Toumba JK, Groen MB, Funke CW, Leemhuis J, Vink J, Woods GF: Excretion, isolation, and structure of a new phenolic constituent of female urine. Nature 287: 738–740, 1980
Setchell KDR, Lawson AM, Mitchell FL, Adlercreutz H, Kirk DN, Axelson M: Lignans in man and in animal species. Nature 287: 740–742, 1980
Axelson M, Setchell KDR: Conjugation of lignans in human urine. Febs Lett 122: 49–53, 1980
Axelson M, Setchell KDR: The excretion of lignans in rats-evidence for an intestinal bacterial source for this new group of compounds. Febs Lett 123: 337–342, 1981
Setchell KDR, Lawson AM, Borriello SP, Harkness R, Gordon H, Morgan DML, Kirk DN, Adlercreutz H, Anderson LC, Axelson M: Lignan formation in man-microbial involvement and possible roles in relation to cancer. Lancet 2: 4–7, 1981
Axelson M, Sjovall J, Gustafsson BE, Setchell KDR: Origins of lignans in mammals and identification of a precursor from plants. Nature 298: 659–660, 1982
Adlercreutz H, Fotsis T, Heikkinen R, Dwyer JT, Woods M, Goldin BR, Gorbach SL: Excretion of the lignans enterolactone and enterodiol and of equol in omnivorous and vegetarian postmenopausal women and in women with breast cancer. Lancet 2: 1295–1299, 1982
Dehennin L, Reiffsteck A, Jondet M, Thibier M: Identification and quantitative estimation of a lignan in human and bovine semen. J Reprod Fert 66: 305–309, 1982
Cooley G, Farrant RD, Kirk DN, Patel S, Wynn S, Buckingham MJ, Hawakes GE, Hursthouse MB, Galas AMR, Lawson AM, Setchell KDR: Structural analysis of the urinary lignan 2,3-bis-(3-hydroxybenzyl)butan-4-olide (‘enterolactone’). A 400 MHz nuclear magnetic resonance study for the solution state and x-ray study for the crystal state. J Chem Soc Perkin Trans 2: 489–497, 1984
Borriello SP, Setchell KDR, Axelson M, Lawson AM: Production and metabolism of lignans by the human faecal flora. J App Bact 58: 37–43, 1985
Walters AP, Knowler JT: Effect of a lignan (HPMF) on RNA synthesis in the rat uterus. J Reprod Fert 66: 379–381, 1982
Hartwell JL: Types of anticancer agents isolated from plants. Cancer Treat Rep 60: 1031–1067, 1976
Barclay AS, Perdue Jr RE: Distribution of anticancer activity in higher plants. Cancer Treat Rep 60: 1081–1113, 1976
Axelson M, Kirk DN, Farrant RD, Cooley G, Lawson AM, Setchell KDR: The identification of the weak oestrogen equol [7-hydroxy-3-(4′-hydroxyphenyl)-chroman] in human urine. Biochem J 201: 353–357, 1982
Martin PM, Horwitz KB, Ryan DS, McGuire WL: Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 103: 1860–1867, 1978
Labarca C, Paigen K: A simple, rapid and sensitive DNA assay procedure. Analyt Biochem 102: 344–352, 1980
Lieberman ME, Jordan VC, Fritsch M, Santos MA, Gorski J: Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogensin vitro. J Biol Chem 258: 4734–4740, 1983
Lieberman ME, Gorski J, Jordan VC: An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogensin vitro. J Biol Chem 258: 4741–4745, 1983
Campen CA, Jordan VC, Gorski J: Opposing biological actions of antiestrogensin vitro andin vivo: induction of progesterone receptor in the rat and mouse uterus. Endocrinology 116: 2327–2336, 1985
Jordan VC, Mittal S, Gosden B, Koch R, Lieberman ME: Structure-activity relationships of estrogens. Envir Health Perspec 61: 97–110, 1985
Jordan VC: Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36: 245–276, 1984
Chalbos D, Vignon F, Keydar I, Rochefort H: Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J Clin Endocr Metab 55: 276–283, 1982
Horwitz KB, McGuire WL: Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem 253: 2223–2228, 1978
Lippman ME, Bolan G, Huff K: The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595–4601, 1976
Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Nat Acad Sci 83: 2496–2500, 1986
Braquet P, Senn N, Robin J-P, Esanu A, Godfraind T, Garay R: Inhibition of the erythrocyte Na+, K+-pump by mammalian lignans. Pharmacol Res Commun 18: 227–239, 1986
Fagoo M, Braquet P, Robin J-P, Esanu A, Godfraind T: Evidence that mammalian lignans show endogenous digitalis-like activity. Biochem Biophys Res Commun 134: 1064–1070, 1986
Setchell KDR, Borriello SP, Hulme P, Kirk DN, Axelson M: Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutrition 40: 569–578, 1984
Tormey DC, Jordan VC: Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 4: 297–302, 1984
Adlercreutz H, Fotsis T, Bannwart C, Wänälä K, Mäkelä T, Brunow G, Hase T: Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens in urine of women on various habitual diets. J Steroid Biochem 25: 791–797, 1986
Elkik F, Guyenne PN, Gompel A, Corvol P, Mercier-Bodard C, Mauvais-Jarvis P, Kuttenn F: Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in postmenopausal women. Am J Obstet Gynecol 143: 888–892, 1982
Holst J, Cajander S, Carlström K, Damber M-G, von Schoultz B: A comparison of liver protein induction in postmenopausal women during oral and percutaneous oestrogen replacement therapy. Brit J Obstet Gynaecol 90: 355–360, 1983
Miller AB: Role of nutrition in the etiology of breast cancer. Cancer 39: 2704–2708, 1977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Welshons, W.V., Murphy, C.S., Koch, R. et al. Stimulation of breast cancer cellsin vitro by the environmental estrogen enterolactone and the phytoestrogen equol. Breast Cancer Res Tr 10, 169–175 (1987). https://doi.org/10.1007/BF01810580
Issue Date:
DOI: https://doi.org/10.1007/BF01810580